RE:RE:RE:Stay focused on the factsI bought THTX when Trogarzo was lunched. At that time Dubuc talked about a potential of at least 1 billion revenue. Then everything becomes inconsistent. Legacy drugs are covering for the costs only. NASH needs huge investment and big pharmas who are making money like ever are reluctant to put a penny in this program. Oncology was brought to the table since they bought katana and the results up to now are very tiny, if not insignificant.
I averaged down many times and i am still a bit below 6$ and I took a hit of 49k by selling half of my THTX portfolio. Many shhareholders are in the same situation where I am. This is our reality today. The rest is bla..bla